Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jeannine Petrig-Schaffland"'
Autor:
Ulrike Obst-Sander, Antonio Ricci, Bernd Kuhn, Thomas Friess, Philipp Koldewey, Andreas Kuglstatter, David Hewings, Annick Goergler, Sandra Steiner, Daniel Rueher, Marie-Paule Imhoff, Noemi Raschetti, Hans-Peter Marty, Aline Dietzig, Caroline Rynn, Andreas Ehler, Dominique Burger, Martin Kornacker, Jeannine Petrig Schaffland, Frank Herting, William Pao, James R. Bischoff, Bruno Martoglio, Yvonne Alice Nagel, Georg Jaeschke
Publikováno v:
Journal of Medicinal Chemistry. 65:13052-13073
Addressing resistance to third-generation EGFR TKIs such as osimertinib via the EGFR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74efbfc9bf49e264df4c98794327c038
https://doi.org/10.1021/acs.jmedchem.2c00893
https://doi.org/10.1021/acs.jmedchem.2c00893
Autor:
Piergiorgio Pettazzoni, James R. Bischoff, Bruno Martoglio, Gabriel Schnetzler, Mitchell P. Levesque, Reinhard Dummer, David S. Hewings, Alessandro Brigo, Marina Bacac, Alison Ribeiro, Dominik Rüttinger, Daniela Krummenacher, Daniel Hunziker, Nicolas Frances, Frank Herting, Jan Eckmann, Jasmin Emmenegger, Cornelia Handl, Martin Kornacker, Jeannine Petrig-Schaffland, Thomas Friess, Caroline Rynn, Jürgen Wichmann
Purpose:Disease progression in BRAF V600E/K positive melanomas to approved BRAF/MEK inhibitor therapies is associated with the development of resistance mediated by RAF dimer inducing mechanisms. Moreover, progressing disease after BRAFi/MEKi frequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2843c44991336c397978b9069d4f8bb4
https://doi.org/10.1158/1078-0432.c.6531080.v1
https://doi.org/10.1158/1078-0432.c.6531080.v1
Autor:
Piergiorgio Pettazzoni, James R. Bischoff, Bruno Martoglio, Gabriel Schnetzler, Mitchell P. Levesque, Reinhard Dummer, David S. Hewings, Alessandro Brigo, Marina Bacac, Alison Ribeiro, Dominik Rüttinger, Daniela Krummenacher, Daniel Hunziker, Nicolas Frances, Frank Herting, Jan Eckmann, Jasmin Emmenegger, Cornelia Handl, Martin Kornacker, Jeannine Petrig-Schaffland, Thomas Friess, Caroline Rynn, Jürgen Wichmann
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13025a5f335ff95cafd17d5c42454b84
https://doi.org/10.1158/1078-0432.22483133
https://doi.org/10.1158/1078-0432.22483133
Autor:
Piergiorgio Pettazzoni, James R. Bischoff, Bruno Martoglio, Gabriel Schnetzler, Mitchell P. Levesque, Reinhard Dummer, David S. Hewings, Alessandro Brigo, Marina Bacac, Alison Ribeiro, Dominik Rüttinger, Daniela Krummenacher, Daniel Hunziker, Nicolas Frances, Frank Herting, Jan Eckmann, Jasmin Emmenegger, Cornelia Handl, Martin Kornacker, Jeannine Petrig-Schaffland, Thomas Friess, Caroline Rynn, Jürgen Wichmann
Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cebd716c1003033988969a2d1ed6815
https://doi.org/10.1158/1078-0432.22483118
https://doi.org/10.1158/1078-0432.22483118
Autor:
Katja Heinig, Filippo Sladojevich, Jeannine Petrig Schaffland, Georg Jaeschke, Alfred Ross, Philipp Koldewey, Saša M. Miladinović, Jin Wang, Caroline Rynn
Publikováno v:
Pharmaceutical Research. 39:653-667
Exploration of the chemical, analytical and pharmacokinetic properties of the API, RO7304898, an allosteric EGFR inhibitor, intended to be developed as a mixture of two rapidly interconverting diastereoisomers with composition ratio of approximately
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a73e622a7a6ab994ee6fe51bf457a35
https://doi.org/10.1007/s11095-022-03234-w
https://doi.org/10.1007/s11095-022-03234-w
Autor:
Gabriel Schnetzler, Alison Ribeiro, Daniela Krummenacher, Caroline Rynn, Alessandro Brigo, Cornelia Handl, Jasmin Emmenegger, Mitchell P. Levesque, Reinhard Dummer, Nicolas Frances, Daniel Hunziker, Bruno Martoglio, Thomas Friess, Martin Kornacker, Jürgen Wichmann, Dominik Rüttinger, David S. Hewings, Jan Eckmann, Piergiorgio Pettazzoni, Jeannine Petrig-Schaffland, James R. Bischoff, Marina Bacac, Frank Herting
Purpose: Disease progression in BRAF V600E/K positive melanomas to approved BRAF/MEK inhibitor therapies is associated with the development of resistance mediated by RAF dimer inducing mechanisms. Moreover, progressing disease after BRAFi/MEKi freque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221a5401152655dfeb8a4a7630ad3143
https://www.zora.uzh.ch/id/eprint/218288/
https://www.zora.uzh.ch/id/eprint/218288/
Autor:
Florentin Lukas Holzem, Martin Brandl, Cordula Stillhart, Annette Bauer-Brandl, Jeannine Petrig Schaffland
Publikováno v:
Holzem, F L, Schaffland, J P, Brandl, M, Bauer-Brandl, A & Stillhart, C 2022, ' Microdialysis and nanofiltration allow to distinguish molecularly dissolved from colloid-associated drug concentrations during biomimetic dissolution testing of supersaturating formulations ', European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, vol. 174, 106166 . https://doi.org/10.1016/j.ejps.2022.106166
European Journal of Pharmaceutical Sciences
European Journal of Pharmaceutical Sciences
Many new drug entities are poorly water- soluble and thus require solubility- enhancing formulations to ensure sufficient bioavailability. On the other hand, it is more and more accepted that not all "dissolved" states of a drug contribute equally to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f487979317fb96b79437994eb34b197
https://pubmed.ncbi.nlm.nih.gov/35283259
https://pubmed.ncbi.nlm.nih.gov/35283259
Autor:
Florentin Lukas Holzem, Anika Weck, Jeannine Petrig Schaffland, Cordula Stillhart, Sandra Klein, Annette Bauer-Brandl, Martin Brandl
Publikováno v:
European Journal of Pharmaceutical Sciences
The majority of new drug entities exhibits poor water solubility and therefore enabling formulations are often needed to ensure sufficient in vivo bioavailability upon oral administration. Several in vitro tools have been proposed for biopredictive s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb49fb3261341fa7fbab17538316779a
https://doi.org/10.1016/j.ejps.2022.106260
https://doi.org/10.1016/j.ejps.2022.106260
Autor:
Carina Cantrill, Caroline Rynn, Prasoon Chaturvedi, Matthias B. Wittwer, Isabelle Walter, Jeannine Petrig Schaffland
Publikováno v:
Drug discovery today. 25(6)
Targeted protein degraders are an emerging modality. Their properties fall outside the traditional small-molecule property space and are in the 'beyond rule of 5' space. Consequently, drug discovery programs focused on developing orally bioavailable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74104587d87ed6b150aa547e3e449e59
https://pubmed.ncbi.nlm.nih.gov/32298797
https://pubmed.ncbi.nlm.nih.gov/32298797
Autor:
Paulina Jakubiak, Rubén Alvarez-Sánchez, Hans Peter Grimm, Jeannine Petrig-Schaffland, Franz Schuler, Björn Wagner
Publikováno v:
Molecular Pharmaceutics. 13:586-598
Drug absorption is a complex process involving dissolution and precipitation, along with other kinetic processes. The purpose of this work was to (1) establish an in vitro methodology to study dissolution and precipitation in early stages of drug dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed78907e50fe5a1fabc351ca4f0f17e7
https://doi.org/10.1021/acs.molpharmaceut.5b00808
https://doi.org/10.1021/acs.molpharmaceut.5b00808